期刊文献+

基于异维A酸案例浅析药品上市许可持有人药品风险控制措施 被引量:2

Risk Control Measures for Marketing Authorization Holder Based on Isotretinoin Case
原文传递
导出
摘要 药品安全直接关系到人们的健康和生命。新版药品管理法提出,药品上市许可持有人应该积极采取有效的药品风险控制措施,以降低不良事件的发生频率和(或)严重性。本文通过介绍美国对异维A酸的风险控制措施的演变历史及具体方法、材料要求,对我国药品上市许可持有人采取的控制药品安全风险的措施提出建议。建议药品上市许可持有人明确各利益相关者的责任,通过制定相关的风险控制措施材料与利益相关者进行沟通,从而保证民众用药安全,以满足《药品管理法》中对"风险管理"的要求。
作者 柳鹏程 王文 王敏娇 池卉卉 任经天 LIU Pengcheng;WANG Wen;WANG Minjiao;CHI Huihui;REN Jingtian(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing 210000;Center for Drug Reevaluation of NMPA,Beijing 100022)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2020年第11期1461-1467,共7页 Chinese Journal of Pharmaceuticals
基金 国家社会科学基金重大项目(15ZDB167) 国家重点研发计划(2018YFC1707409) 江苏高校哲学社会科学研究基金项目(2017SJB0060)。
  • 相关文献

参考文献5

二级参考文献28

  • 1陈敏.利益相关者理论与现代公司共同治理框架构建[J].湖南科技大学学报(社会科学版),2003,6(4):61-63. 被引量:3
  • 2Tsintis P, La Mache E. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implica- tions[J]. Drug Saf,2004,27(8):509-517.
  • 3REMS white paper. Summary of the REMS stakeholder meeting on improving program design and implementation [ J ]. J Am Pharm Assoc ,2003,51 ( 3 ) :340-358.
  • 4Medication Guides. Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) [ EB/ OL]. http ://wunv. fda. gov/downloads/Drugs/GuidanceCom- plianceRegulatorylnformation/ Guidances/ UCM244570. pdf , 2011-11/2012-04-10.
  • 5Implementation of the Action Plan to Further Progress the European Risk Management Strategy: Rolling Two-Year Work Programme (2008-2009) [ EB/OL]. http://wunv, emea. europa. eu/docs/en_GB/document_librury/Regulatory_and_.pro- cedural_guideline/2009/lO/WC500006297, pdf , 2007-03-12/ 2012-04-10.
  • 6Frau S, Font Pous M, Luppino MR, et al. Risk Management Plans: are they a tool for improving drug safety? [J] . Eur J Clin Pha~ol,2010 ,66(8) :785-790.
  • 7Giezen TJ, Mantel-Teeuwisse AK, et al. Evaluation of postauthorization safety studies in the first cohort of EU Risk Man- agement Plans at time of regulatory approval [ J ]. Drug Saf, 2009,32(12) :1175-1187.
  • 8Chung R. US. healthcare stakeholders uncertain about benefits of risk evaluation program [ EB/OL]. http://csdd, tufts. edu/news/eomplete_story/pr_ir_jan-feb_2011, html , 2011-01 - 12/2012-04-10.
  • 9Road to 2015 :The European Medicines Agency's contribution to science, medicines and health [ EB/OL ]. http://www. emea. europa, eu/ docs/ en_GB/ document_library/ Report /2010/ 01/WC500067952. pdf ,2010-12-16/2012-1M-lO.
  • 10Goldman SA. Communication of medical product risk: how effective is effective enough? [ J ]. Drug Saf, 2004,27 ( 8 ) : 519-534.

共引文献40

同被引文献33

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部